BACKGROUND: The proposed revisions of the ICD and DSM diagnostic systems have led to increased interest in evaluation of diagnostic criteria. This report focuses on the DSM-IV requirement that episodes of generalized anxiety disorder (GAD) must persist for at least 6 months. Community epidemiological data are used to study the implications of changing this requirement in the range 1-12 months for estimates of prevalence, onset, course, impairment, co-morbidity, associations with parental GAD, and sociodemographic correlates. METHOD: Data come from the US National Comorbidity Survey Replication (NCS-R), a US household survey carried out during 2001-2003. Version 3.0 of the WHO Composite International Diagnostic Interview (WMH-CIDI) was used to assess DSM-IV anxiety disorders, mood disorders, substance disorders, and impulse-control disorders. RESULTS: Lifetime, 12-month, and 30-day prevalence estimates of DSM-IV GAD changed from 6.1%, 2.9%, and 1.8% to 4.2-12.7%, 2.2-5.5%, and 1.6-2.6% when the duration requirement was changed from 6 months to 1-12 months. Cases with episodes of 1-5 months did not differ greatly from those with episodes of > or = 6 months in onset, persistence, impairment, co-morbidity, parental GAD, or sociodemographic correlates. CONCLUSIONS: A large number of people suffer from a GAD-like syndrome with episodes of < 6 months duration. Little basis for excluding these people from a diagnosis is found in the associations examined here.
BACKGROUND: The proposed revisions of the ICD and DSM diagnostic systems have led to increased interest in evaluation of diagnostic criteria. This report focuses on the DSM-IV requirement that episodes of generalized anxiety disorder (GAD) must persist for at least 6 months. Community epidemiological data are used to study the implications of changing this requirement in the range 1-12 months for estimates of prevalence, onset, course, impairment, co-morbidity, associations with parental GAD, and sociodemographic correlates. METHOD: Data come from the US National Comorbidity Survey Replication (NCS-R), a US household survey carried out during 2001-2003. Version 3.0 of the WHO Composite International Diagnostic Interview (WMH-CIDI) was used to assess DSM-IV anxiety disorders, mood disorders, substance disorders, and impulse-control disorders. RESULTS: Lifetime, 12-month, and 30-day prevalence estimates of DSM-IV GAD changed from 6.1%, 2.9%, and 1.8% to 4.2-12.7%, 2.2-5.5%, and 1.6-2.6% when the duration requirement was changed from 6 months to 1-12 months. Cases with episodes of 1-5 months did not differ greatly from those with episodes of > or = 6 months in onset, persistence, impairment, co-morbidity, parental GAD, or sociodemographic correlates. CONCLUSIONS: A large number of people suffer from a GAD-like syndrome with episodes of < 6 months duration. Little basis for excluding these people from a diagnosis is found in the associations examined here.
Authors: Ayelet Meron Ruscio; Wai Tat Chiu; Peter Roy-Byrne; Paul E Stang; Dan J Stein; Hans-Ulrich Wittchen; Ronald C Kessler Journal: J Anxiety Disord Date: 2006-11-21
Authors: Ayelet Meron Ruscio; Michael Lane; Peter Roy-Byrne; Paul E Stang; Dan J Stein; Hans-Ulrich Wittchen; Ronald C Kessler Journal: Psychol Med Date: 2005-12 Impact factor: 7.723
Authors: Christina M Sheerin; Mackenzie J Lind; Emily A Brown; Charles O Gardner; Kenneth S Kendler; Ananda B Amstadter Journal: Depress Anxiety Date: 2017-11-24 Impact factor: 6.505
Authors: Mackenzie J Lind; Sage E Hawn; Christina M Sheerin; Steven H Aggen; Robert M Kirkpatrick; Kenneth S Kendler; Ananda B Amstadter Journal: Depress Anxiety Date: 2017-01-16 Impact factor: 6.505
Authors: Kay Jüngling; Thomas Seidenbecher; Ludmila Sosulina; Jörg Lesting; Susan Sangha; Stewart D Clark; Naoe Okamura; Dee M Duangdao; Yan-Ling Xu; Rainer K Reinscheid; Hans-Christian Pape Journal: Neuron Date: 2008-07-31 Impact factor: 17.173